9.735
price down icon1.86%   -0.195
 
loading
전일 마감가:
$9.93
열려 있는:
$9.94
하루 거래량:
888.31K
Relative Volume:
0.21
시가총액:
$2.30B
수익:
$503.49M
순이익/손실:
$-53.47M
주가수익비율:
-37.44
EPS:
-0.26
순현금흐름:
$-26.89M
1주 성능:
-2.16%
1개월 성능:
-7.98%
6개월 성능:
+27.05%
1년 성능:
+60.28%
1일 변동 폭
Value
$9.705
$10.02
1주일 범위
Value
$9.705
$10.15
52주 변동 폭
Value
$6.00
$11.31

바이오크리스트 Stock (BCRX) Company Profile

Name
명칭
Biocryst Pharmaceuticals Inc
Name
전화
919-859-1302
Name
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
직원
580
Name
트위터
@biocrystpharma
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
BCRX's Discussions on Twitter

BCRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
9.75 2.30B 503.49M -53.47M -26.89M -0.26
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
21.88 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.63 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.47 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.96 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.91 20.17B 16.54B -1.64B 749.00M -1.45

바이오크리스트 Stock (BCRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-29 개시 Cantor Fitzgerald Overweight
2025-02-25 개시 Wedbush Outperform
2023-11-20 재개 JP Morgan Overweight
2023-09-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-08-04 업그레이드 Jefferies Hold → Buy
2023-07-13 업그레이드 BofA Securities Neutral → Buy
2023-02-22 업그레이드 Needham Hold → Buy
2022-11-02 업그레이드 Evercore ISI In-line → Outperform
2022-08-05 다운그레이드 Evercore ISI Outperform → In-line
2022-08-05 다운그레이드 Oppenheimer Outperform → Perform
2022-04-18 다운그레이드 Barclays Overweight → Equal Weight
2022-04-11 다운그레이드 BofA Securities Buy → Neutral
2021-12-10 개시 Oppenheimer Outperform
2021-08-06 다운그레이드 Jefferies Buy → Hold
2021-08-03 개시 Cantor Fitzgerald Overweight
2021-03-01 개시 Cowen Outperform
2020-09-29 재개 JP Morgan Overweight
2020-06-17 개시 BTIG Research Neutral
2020-05-05 업그레이드 Barclays Equal Weight → Overweight
2019-11-15 업그레이드 BofA/Merrill Neutral → Buy
2019-05-24 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2018-11-16 재개 Piper Jaffray Overweight
2018-08-08 재개 JP Morgan Overweight
2018-07-17 업그레이드 BofA/Merrill Underperform → Neutral
2018-06-22 개시 Seaport Global Securities Neutral
2018-01-02 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2017-12-20 개시 Barclays Equal Weight
2017-09-15 개시 RBC Capital Mkts Sector Perform
2017-09-06 업그레이드 JP Morgan Neutral → Overweight
2017-09-06 업그레이드 Jefferies Hold → Buy
2017-02-16 개시 Ladenburg Thalmann Buy
2016-08-12 업그레이드 Piper Jaffray Neutral → Overweight
2016-08-04 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 재확인 FBR Capital Outperform
2016-02-09 다운그레이드 JP Morgan Overweight → Neutral
2016-02-09 다운그레이드 Needham Buy → Hold
모두보기

바이오크리스트 주식(BCRX)의 최신 뉴스

pulisher
Jun 18, 2025

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Nasdaq

Jun 18, 2025
pulisher
Jun 16, 2025

BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News

Jun 16, 2025
pulisher
Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

Sector Update: Health Care Stocks Lean Lower Premarket Friday - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

ORLADEYO® (berotralstat) Approved in Colombia | BCRX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Orladeyo approved for reimbursement in the Netherlands - Angioedema News

Jun 12, 2025
pulisher
Jun 11, 2025

Marburg Virus Disease Pipeline 2025: Therapies Under - openPR.com

Jun 11, 2025
pulisher
Jun 10, 2025

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 46.47% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews

Jun 10, 2025
pulisher
Jun 09, 2025

BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : BioCryst Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

California State Teachers Retirement System Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCR - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst Achieves Reimbursement for ORLADEYO Across all Major Eu - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | BCRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

New Strong Buy Stocks for June 4th - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Orladeyo effective in HAE patients of different ages, data show - Angioedema News

Jun 05, 2025
pulisher
Jun 05, 2025

BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : BioCryst Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 04 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Best Momentum Stock To Buy For June 4th - Barchart.com

Jun 04, 2025
pulisher
Jun 04, 2025

biocryst pharmaceuticals extends cfo consulting agreement By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Best Momentum Stock to Buy for June 4th - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

biocryst pharmaceuticals extends cfo consulting agreement - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

BioCryst Extends Consulting Agreement with Former CFO - TipRanks

Jun 04, 2025
pulisher
Jun 03, 2025

BioCryst Pharmaceuticals Inc (BCRX) Shares Up 3.59% on Jun 3 - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

BioCryst (BCRX) Awards Restricted Stock Units to New Employees | - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 03, 2025

바이오크리스트 (BCRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$13.89
price up icon 2.85%
$8.885
price down icon 0.73%
$127.43
price down icon 0.61%
$286.18
price down icon 1.37%
drug_manufacturers_specialty_generic RDY
$15.47
price down icon 0.83%
$16.91
price down icon 0.99%
자본화:     |  볼륨(24시간):